Stocks To Watch: Oct. 22

(RTTNews) - What made these stocks interesting?

Netflix Inc. (NFLX) reported stellar results for the third quarter and issued upbeat forecast for the fourth quarter.

- Q3 profit rose to $31.8 mln or $0.52 per share versus $7.7 mln or $0.13 per share last year. Consensus - $0.49 per share.

- Q3 revenues grew to $1.11 billion from $905.1 million last year. Consensus - $1.10 billion.

- Sees Q4 EPS between $0.47 and $0.73 per share. Consensus - $0.46 per share.

- Expects to improve its domestic subscriber base to a range of 32.7 mln - 33.5 mln, and international subscribers to 10.1 mln - 10.9 mln.

--------------------------------------

Oxygen-carrying therapeutics developer Oxygen Biotherapeutics Inc. (OXBT) signed a definitive agreement to acquire certain assets of Phyxius Pharma, a privately-held biopharmaceutical company, in a transaction valued at about $4.8 million in stock.

Oxygen Biotherapeutics will acquire the exclusive rights to develop and commercialize levosimendan in North America, as well as integrating three key Phyxius Pharma executives into the company's management team.

Upon closing of the transaction, Phyxius Pharma Co-Founder and CEO, John Kelley is to become CEO of Oxygen Biotherapeutics. Michael Jebsen, Oxygen Biotherapeutics' current Interim CEO and CFO, will remain serving as the CFO.

The asset purchase agreement brings to Oxygen Biotherapeutics not only the exclusive rights in North America to develop and commercialize levosimendan for the specific indication of prevention and treatment of low cardiac output syndrome, but also the FDA's approval of Fast Track status for a Phase 3 trial, and the FDA's SPA which represents agreement with the Phase III clinical trial's study protocol.

------------------------------------------

Polaris Industries Inc. (PII) increased and narrowed its fiscal 2013 guidance

Now sees FY13 EPS from cont. ops. between $5.30 and $5.37 per share versus prior view of $5.20 - $5.30. Consensus - $5.36 per share.

Expects FY13 sales to grow in the range of 15% - 16% versus previous target of 13% - 15%.